Fragile Females: Case Series of Epilepsy in Girls With

Girls with pathogenic variants in

Informations de copyright

Copyright © 2019 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: Dr Myers reports grants from Citizens United for Research in Epilepsy, Dravet Canada, and the Research Institute of the McGill University Health Centre; he has also received a travel grant from Zynerba Pharmaceuticals and is a trial site investigator for LivaNova. Dr Sadleir is a trial investigator for a study with Zynerba Pharmaceuticals; she has acted as a consultant for Nutricia, has received funding for travel from Union Chimique Belge and Seqirus, and is a consultant for the Epilepsy Study Consortium. She received research funding from the Health Research Council of New Zealand and Cure Kids (New Zealand). Dr Scheffer reports grants from the National Health and Medical Research Council and National Institutes of Health during the conduct of the study and personal fees from Union Chimique Belge, GlaxoSmithKline, Eisai, BioMarin Pharmaceutical, Nutricia, GW Pharmaceuticals, Athena Diagnostics, and Xeonon outside the submitted work as well as other fees from Zogenix. In addition, Dr Scheffer has a patent for diagnostic and therapeutic methods for epilepsy and mental retardation limited to females, with royalties paid to the University of Melbourne (Central Adelaide Local Health Network), and a patent for methods of treating and diagnosing epilepsy by detecting mutations in the SCN1A gene, with royalties paid to Bionomics Inc and licensed to various diagnostic companies. Dr Legault is a trial site investigator for Novartis; the other authors have indicated they have no potential conflicts of interest to disclose.